RPG Life Sciences Limited has informed the Exchange about Investor Presentation
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
RPG Life Sciences reported strong Q4 FY26 results with revenue up 23.6% YoY to ₹176.9 crore and EBITDA up 48% to ₹45.2 crore, lifting margins to 25.6% from 17.5%. Q4 profit after tax (excluding one-time items) jumped 58.1% to ₹29.3 crore. For the full year FY26, revenue grew 8.3% to ₹707.5 crore and PAT stood at ₹111.7 crore, though full-year margins slipped slightly due to a fire incident that hit the API segment. The Domestic Formulations business, which contributes nearly 69% of sales, grew 13.7% and outpaced the Indian pharma market by 1.6x for the full year, making it the 4th fastest-growing pharma company in Q4. Management laid out a 7-pillar growth plan targeting ₹200+ crore for the immunosuppressant portfolio and ₹100+ crore for the Naprosyn brand, while confirming an M&A framework is in place with multiple proposals under evaluation. ICRA reaffirmed the company's A+ rating with stable outlook, noting it remains debt-free.
Strong Q4 beat and margin expansion are positive for shareholders, though the slightly weaker full-year margins and API segment disruption are minor concerns. The debt-free status, brand-building targets, and active M&A pipeline point to a growth-focused outlook that could support investor sentiment.